Dr. Blair Leavitt

A scientist and physician, Dr. Leavitt’s time (both clinical and research) is dedicated to developing new treatments for genetic brain disorders such as Frontotemporal Dementia, Huntington’s disease, and amyotrophic Lateral sclerosis (or Lou Gehrig’s disease). Dr. Leavitt is currently a Senior Scientist at the Centre for Molecular Medicine and Therapeutics (CMMT), the Co-Director of the UBC Neurogenetics Clinic, Director of Research at the UBC Centre for Huntington’s disease and a founding Editor-in-Chief of The Journal of Huntington’s Disease. A long-standing member of the Huntington Study Group (HSG), HD clinical trial investigator, and neurologist at the UBC HD medical clinic in Vancouver. He recently has become the Co-Chair of the HSG and Vice-president of HSG inc. Dr. Leavitt completed his medical training at McGill University, medical internship at Columbia-Presbyterian Hospital, and finished his clinical training in neurology at Cornell University and Harvard Medical School. During his four years at Harvard Medical School, he also completed a post-doctoral fellowship investigating neural stem cell transplantation as a potential treatment for neurodegenerative diseases such as Alzheimer’s disease. The Leavitt laboratory at the CMMT is dedicated to the development of novel mouse models of human neurologic disease, with the express goal of accelerating the progress of treatments for genetic brain disorders from the bench to the clinic.  Dr. Leavitt’s development of several important mouse models of human neurodegenerative diseases has enabled pre-clinical experimental therapeutic trials in these mice that are now being translated into human clinical trials. Clinically, he is involved in the translation into human clinical trials of agents first tested in mice, and he is currently an investigator on six ongoing human clinical therapeutic trials and biomarker studies.  Dr. Leavitt is also the Director of the CMMT transgenic mouse facility.

Dr. Blair Leavitt Grants